samedan logo
 
 
 
spacer
home > pmps > winter 2001 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

This year has been a milestone - the first year of the millennium has been overshadowed by the tragic events of September 11th, followed by the war in Afghanistan. These events have had their impact on our industry in at least two ways. Firstly, many visitors and exhibitors to the events planned in October were unable to travel. As a result, for our US colleagues in particular, planned meetings didn't happen.

Nevertheless, it was interesting to see many of the European and Asia Pacific contract pharmaceutical manufacturers and suppliers at the CPhI in London. Secondly, the increased threat of bioterrorism focused the minds of pharma and biotech players and their investors in the scramble for dwindling stocks of antibiotics effective against anthrax, while orders for the

smallpox vaccine by the US government have been of benefit to UK suppliers. In the biotech sector, companies may be looking further ahead to anticipate their leading edge technologies being overtaken. Formation of alliances, partnerships or M&As could be part of a defensive strategy.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Along with our sister publications, EBR and EPC, this issue of PMPS is published by our new owners Samedan Ltd. PMPS Winter 2001 aims to provide interesting reading over the festive season.
spacer
Dr Patricia Lobo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting The Efficacy And Safety of Cefiderocol For The Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement